Skip Navigation LinksHome > March 2014 - Volume 26 - Issue 2 > Systemic treatment of malignant pleural mesothelioma: new ag...
Current Opinion in Oncology:
doi: 10.1097/CCO.0000000000000053
LUNG AND MEDIASTINUM: Edited by Robert Pirker

Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements

Christoph, Daniel C.; Eberhardt, Wilfried E.E.

Collapse Box

Abstract

Purpose of review

Malignant pleural mesothelioma (MPM) is a rare malignancy with limited therapeutic options and its incidence is still increasing in both Europe and the developing nations. Prognosis of MPM patients is poor even if the median survival durations have been slightly improved after the introduction of the up-to-date chemotherapy combination with pemetrexed and cisplatin. There is a continuing unmet need to develop better systemic treatment for this disease, but the rarity of the tumor type creates formidable challenges in clinical trial research.

Recent findings

Better understanding of the molecular machinery of MPM leads to the design and synthesis of novel compounds targeted against pathways identified as crucial for MPM cell proliferation and metastasis. Most efforts aim at improving standard first-line therapy, or developing effective second-line treatments. Several classes of drugs are currently being explored either in combination with cisplatin and pemetrexed or as single agent for relapsed or progressive MPM.

Summary

This review focuses on several ongoing or recently completed clinical trials investigating novel, promising agents as first-line or second-line therapy for advanced MPM.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.